Overview
AMD is a major cause of vision loss, which leads to enormous socioeconomic and healthcare costs. The numbers affected is rising rapidly, due in part, to an ageing population. A subtype called polypoidal choroidal vasculopathy (PCV) makes up 50% of AMD in Asians, but current understanding of this subtype remains limited.
Professor Gemmy Cheung from the Singapore Eye Research Institute, together with her diverse team of retinal specialists, clinician-scientists, and basic scientists, seek to reduce vision loss and blindness from AMD and improve quality of life for patients with this disease through the Translational Asian Age-related macular degeneration Programme (TAAP), funded through an Open Fund –Large Collaborative Grant from the National Medical Research Council in Singapore.
TAAP adopts a “bench-to-bedside-to-population” approach, with the following 5-inter-linked themes which addresses key research questions aligned to clinical needs and strong industry interest:
More about TAAP here:
Article - https://www.scientia.global/professor-gemmy-cheung-the-translational-asian-age-related-macular-degeneration-program-improving-age-related-macular-degeneration-outcomes/
Podcast - https://open.spotify.com/episode/3qq1lGYxjd71aQ7GZklsfw
Our 5-year Vision
To develop paradigm shifts in our conceptualisation and understanding of Asian AMD, including PCV, that will lead to novel classification and evidence-based cost effective diagnostics, prevention and treatment strategies.
Clinical and Healthcare Significance
The proposed TAAP programme will enhance our understanding of not only the basic mechanisms of AMD and PCV, but also translate basic research into clinical studies and commercialisation outcomes, develop novel imaging diagnostics, improve therapeutic strategies as well as lay the foundation for future cell-based therapy and rehabilitation technologies. The improved health outcome for patients with AMD would significantly reduce the financial burden on both the individuals as well as the population at large. The proposed multi-disciplinary research project will improve coordination and collaboration of research efforts across Singapore and other Asian countries, and lead to the establishment of national infrastructure platforms and coordinated services for AMD, within the region. TAAP is aligned to the Ministry of Health’s (MOH) priorities in “ageing” and “precision medicine”.
Media releases
The Straits Times, 18 April 2018
Title: MOH awards $60M to 3 research projects
SingVision, 15 Oct 2018, Issue 2 (2018)
Title: SERI and SNEC awarded $24M grant for AMD study
The Straits Times, 1 Dec 2018
Title: Sights set on more effective way to treat eye diseases
938NOW, 23 May 2019
Title: Professor Gemmy Cheung invited for a radio interview with Daniel Martin
Touch Medical Media Services, Euretina Congress 2019, 13 Sept 2019
Title: Clinical Characteristics in AMD
Channel News Asia, 7 Jan 2020
Title: STANCE NTU collaboration
BioSpectrum Asian Edition, 28 February 2020
Title: Gemini Therapeutics and SERI to explore new targets for AMD
The Straits Times, 1 Aug 2020
Title: Timely eye injections help preserve vision. Interviews with Prof Gemmy Cheung and Dr Kelvin Teo
Mediacorp Channel 5 – Body and Soul – Episode 5, Dec 2020
Title: Dr Kelvin Teo discussed Age-related Macular Degeneration and the use of the Alleye app for self-monitoring of retinal diseases
Mediacorp radio, CNA 938 Live, 3 Feb 2021
Title: Live interview with Dr Kelvin Teo. The interview discussed key findings from a research on local AMD patients
Ocular Surgery News, 25 March 2021
Title: Experts offer opinions on global trends in retina, part 2. (featuring Professor Gemmy Cheung)
Today Online, 29 March 2021
Title: The world looks brighter with better eyesight
Zaobao, 8 June 2021
Title: 老年黄斑病变患者 疫情下如何控制病情
Businesswire, 11 October 2021
Title: RxCell Inc., A*STAR’s IMCB, NUS, and SERI Collaborate to Develop Cellular Therapeutics for Age-related Diseases
Recent Publications
Theme 1
Theme 2
Theme 3/4
Theme 5
Patients and Participants
This study will be of major clinical and health care interest. Our ongoing clinical studies, supported by the experienced research coordinators from SERI, have been actively engaging patients. All new patients referred for AMD and PCV are approached by our research team, who will educate patients on the disease, common treatment and expectations. This information forms part of the patient counselling and encourages patients to participate in clinical studies to help improve current understanding and treatment outcome of this potentially blinding condition.
TAAP Clinical Trials (recruiting)
If you are interested in participating in the clinical trials, please contact us here.
Research and Industry Collaborators
TAAP provides a rare and unique opportunity to allow clinicians and basic scientists to come together with industry players in addressing crucial medical research questions, in a multi-faceted manner.
We have a strong, long-standing collaborative partnership with academics and industry with an interest in AMD and PCV.
Our Collaborators include:
Local Academic collaborators
National University Hospital System (NUHS)
Tan Tock Seng Hospital (TTSH)
Duke-NUS Medical School (Duke-NUS)
Agency for Science, Technology and Research (A-STAR)
Nanyang Technological University (NTU)
International Academic Collaborators
University of Sydney, Australia
University of Melbourne, Australia
Flinders University, Australia
Beijing Tongren Hospital, China
The Chinese University of Hong Kong, Hong Kong
Hong Kong Eye Hospital, Hong Kong
Taipei Veterans General Hospital, Taiwan
Huazhong University of Science and Technology
Osaka University, Japan
Kyoto University, Japan
Nihon University Hospital, Japan
Seoul National University Bundang Hospital, Korea
The Catholic University of Korea, Korea
Queen’s University Belfast, UK
Ruprecht-Karls-University Heidelberg, Germany
Washington University School of Medicine, USA
Duke University Eye Centre, USA
Doheny Eye Institute, USA
Industry Collaborators
Topcon Corporation, Japan
Bayer, Singapore
Novartis Singapore
Notal Vision, USA
Gemini Therapeutics
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
AMED Japan Agency for Medical Research and Development
Ferring, Switzerland
SanBio Co. Ltd., Japan
Nidek Co. Ltd., Singapore
Johnson & Johnson Vision Care Inc, Singapre
Cylite Pty Ltd, Australia
Medi-Whale Inc
Boehringer-Ingelheim, Germany
Roche, Switzerland
We are keen to discuss and develop new industry partnerships, and research and development collaborations. You may contact us here.